Dicerna Pharmaceuticals Raises Additional $4M in Series B, Bringing Total to $29M | GenomeWeb

Dicerna Pharmaceuticals said this week that it has raised an additional $4 million in a second closing of Series B equity financing, bringing the total raised in this round to $29 million.

The company raised $25 million in the Series B in August (GSN 8/12/2010).

SR One, the venture capital arm of GlaxoSmithKline, participated in the financing as a new investor, joining existing investors Oxford Bioscience Partners, Skyline Ventures, Abingworth, and Domain Associates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.